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Background: Development of drug-resistance mutations is the main cause of failure in
antiretroviral therapy. In Brazil, there is scarce information on resistance pattern for patients
failing antiretroviral therapy.
Objectives: To define the HIV mutational profile associated with drug resistance in Brazilian
patients from 5  large cities, after first, second or further failures to antiretroviral therapy.
Methods:  We  reviewed genotyping results of 1520 patients failing therapy in five Brazilian
cities. Frequency of mutations, mean number of active drugs, viral susceptibility to each
antiretrovirals drug, and regional differences were assessed.
Results: Mean time of antiretrovirals use was 22.7 ±  41.1 months. Mean pre-genotyping viral
load was 4.2 ± 0.8 log (2.1 ± 2.0 after switching antiretrovirals). Mean number of remaining
active  drugs was 9.4, 9.0, and 7.9 after 1st, 2nd, and 3rd failure, respectively. We  detected
regional  variations in drug susceptibility: while BA and RS showed the highest (∼40%) resis-
tance  level to ATV/r, FPV/r and LPV/r, in the  remaining cities it  was around half of this rate. We
detected 90% efavirenz/nevirapine resistance in SP, only 45% in RS, and levels between 25%
and  30% in the other cities. Regarding NRTI, we found a similar pattern, with RJ presenting
the  highest, and CE the  lowest susceptibility rates for all NRTI. Zidovudine resistance was
detected in only 3% of patients in RJ, against 45–65% in the other cities. RJ and RS showed 3%
resistance to tenofovir, while in CE it  reached 55%. DRV/r (89–97%) and etravirine (61–85%)
were the most active drugs, but again, with a  wide variation across cities.
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Conclusions: The resistance mutational profile of Brazilian patients failing antiretroviral
therapy is quite variable, depending on the  city where patients were tested. This variation
likely reflects distinctive choice of antiretrovirals drugs to initiate therapy, adherence to
specific drugs, or circulating HIV-1 strains. Overall, etravirine and DRV/r remain as the most
active  drugs.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Resistance to antiretrovirals (ARV) is a usual finding in HIV-
infected patients failing antiretroviral therapy (ART). The
mutational pattern after initial failure is quite predictable, but
in subsequent ARV regimens it may become very complex, and
frequently limit the available treatment options.1 In addition,
the use of different algorithms for interpretation of mutational
profiles obtained by genotypic tests might provide divergent
results regarding sensitivity of HIV to ARV drugs to be used in
salvage therapy regimens.
The Brazilian Ministry of Health (BMOH) provides free
universal access to ARV drugs since the beginning of the
epidemic. The current official recommendation for patients
failing therapy is to choose salvage regimens according to
HIV-1 antiretroviral drug sensitivity, assessed by genotypic
resistance tests.2 However, although resistance tests are sup-
posed to be  readily available, many logistical problems have
impaired this strategy, due to long turnaround time of results
in some areas of the country, and to the fact that many  physi-
cians decide to  switch therapy without a  previous resistance
test.
In addition, the genotypic characteristics of HIV in patients
failing ART is still unclear, since the available information is
restricted to small, specific groups of patients, from differ-
ent sites. In  Brazil, circulation of different viral subtypes has
been reported, with variable prevalence according to different
regions.3–6 There is  scarce information on regional differences
regarding mutational profile, availability of remaining active
drugs, and the variability of susceptibility rates for different
ARV drugs, according to the use of different algorithms.
In the last years, the routine tool for genotypic interpreta-
tion was a locally developed algorithm (RENAGENO), in which
interpretation of results are released along with that provided
by TruGene platform (Siemens Healthcare Diagnostics, Inc,
USA).7 In last decade BMOH trained around 400 doctors for
interpreting genotypic reports, and to provide suggestions for
the next ARV regimen to be used by physicians. This strategy
made easier the selection of appropriate ARV drugs in salvage
therapy regimens.
In the present work we evaluated a large number of resis-
tance tests, in  five large Brazilian cities. This allowed us to
define the frequency of mutations after first or subsequent
failures, as well  as  the differences between drug susceptibility
rates across these locations, and mean number of remaining
active drugs for patients at each site.
Methods
We  reviewed reports of resistance tests performed from 2010
to 2013 in  five large Brazilian cities, from different regions.
All available reports from patients tested in reference centers
for HIV care in  Porto Alegre (RS, South region), Campinas (SP,
Southeast region), Rio de Janeiro (RJ, Southeast region), Vitoria
(ES, Southeast region), Salvador (BA, Northeast region), and
Fortaleza (CE, Northeast region) were reviewed.
Frequency of detected drug-resistance mutations (DRM),
previous use of antiretroviral drugs, and patients’ characteris-
tics were evaluated, and the mean number of fully active drugs
was  calculated for each city and for the overall study popula-
tion. Fully active drugs were attributed a weight equal to one.
Drugs partially active (“intermediate resistance”) were given a
0.5 weight, while for complete resistance the attributed weight
was  zero. The susceptibility for each drug was compared by
using the Brazilian algorithm of interpretation (RENAGENO),
according to patient’s origin.7
Statistical  analyses
We used SPSS (Statistical Package for Social Sciences) ver-
sion 17.0 to perform all statistical calculations. Descriptive
analyses (frequencies, mean, standard deviations) were per-
formed, and comparisons of frequencies between groups were
assessed by chi-square test.
Results
A  total of 1512 genotypic tests was reviewed in the study
period, but only 1481 had enough information to be included
in the analysis. Most tests were performed in patients from
Salvador (552), followed by Vitória (246), Fortaleza (219), Rio
de  Janeiro (152), Porto Alegre (112), and Campinas (102 tests).
Table 1 shows the main characteristics of patients submitted
to HIV-1 genotyping.
Most patients (675 subjects – 43.1%) were failing their sec-
ond ARV regimen, 431 (37.8%) were failing their first ARV
treatment, and the remaining 375 (15%) had already failed
three or more  regimens. The most frequently detected DRM
(>10%) are shown in Tables 2  and 3. The susceptibility rates
of HIV-1 strains to each ARV drug in  the five different loca-
tions are shown in Figure 1a–c. It should be pointed out the
clear difference between the susceptibility rates to reverse
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Table 1 – Characteristics of patients submitted to HIV-1 genotyping in five different cities in Brazil from 2010 to 2013.
Overall BA  SP RS CE RJ ES
Number of tests  1383 552 102 112 219 152  246
Age 41.1 ± 11.0 41.8 ± 9.3  43.8 ± 10.2 44.3 ± 8.8 42.0 ±  9.8 39.0 ± 10.6 37.2 ± 15.3
Pre-genotyping
VL (log)
4.2 ± 0.8  4.2 ± 0.9  4.1 ± 0.7 4.3 ± 1.2 4.1  ±  0.6 4.2 ± 0.7 4.3 ± 0.7
Pre-genotyping
CD4 count
(cells/mm3)
299 ± 251 313 ± 260 282 ± 253 245 ± 198 285 ±  253 267  ± 239 263 ± 247
All results are expressed as  mean ±  standard deviation.
Table 2 – Frequency (%)  of most common drug-resistance mutations to HIV-1 reverse transcriptase inhibitors, according
to the patient’s origin.
Mutation All samples BA  SP RS CE RJ  ES
41L 21.2 31.0 19.4 36.6 20.4 10.5 0.0
67N 22.9 27.5 17.5 30.9 20.0 9.9  21.5
70R 18.2 23.2 6.8 22.0 15.6 9.9  17.9
184V 70.9 81.2 54.4 74.0 65.6 55.9 68.1
210W 15.7 20.5 9.7 21.1 11.6 4.6  15.9
215F 11.3 13.6 10.7 18.7 13.2 5.3  4.4
215Y 16.5 26.1 0.0 17.9 19.2 0.0  8.8
103N 40.0 44.0 50.5 28.5  38.0 30.3 40.6
108I 10.2 11.8 12.6  4.1  11.6 5.9  10.0
Table 3 – Most frequent (>10%) drug-resistance mutations in HIV-1 protease, according to origin of sample.
Mutation All samples BA  SP RS CE RJ  ES
10I 17.7 19.2 19.4 27.6 10.0 11.8 20.3
10V 10.6 13.0 13.6 6.5  8.4 4.6  11.6
20R 15.0 14.3 11.7 26.0 13.6 10.5 16.7
36I 47.0 47.3 49.5 53.7 46.8 40.1 46.2
46I 15.3 19.2 8.7 26.8 8.4 9.9  13.9
54V 12.6 13.9 13.6 30.9 5.2 5.3  12.0
60E 11.0 9.2 8.7 0.0  9.2 21.7 16.3
62V 24.4 23.7 26.2 0.0  24.8 37.5 28.7
71V 14.1 20.8 12.6 28.5 12.0 5.9  0.0
90M 12.6 15.9 11.7 23.6 8.4 2.0  10.8
93L 23.3 21.0 29.1 3.3  22.4 24.3 36.3
transcriptase inhibitors (zidovudine – AZT, tenofovir – TDF,
didanosine –  ddI, stavudine – d4T, nevirapine – NVP, efavirenz
–  EFV, and etravirine – ETV) among tests originated from differ-
ent sites (p < 0.001 for all comparisons). For instance, genotypic
tests of patients from SP showed the highest rate of resistance
to EFV and NVP (92%), while in  RS almost 2/3 (58%) of tests
detected susceptibility to these non-nucleoside reverse trans-
criptase inhibitors (NNRTI, p < 0.001). The remaining three
sites shared a  similar profile, with detected susceptibility for
NNRTI in around 1/3 of samples. We  observed the same pat-
tern for all drugs, with a large variability in  susceptibility rates
for different cities, especially for some ARV: in  CE we detected
resistance to ETR in 52%  of samples, while in RS only 8% of
tests showed resistance to this drug (p < 0.001).
The resistance rates to protease inhibitors (PI) also signifi-
cantly varied according to  origin of patients. Patients tested
in BA or RS showed the highest (30–50%) resistance rates
to boosted atazanavir (ATV/r), fosamprenavir (FPV/r), and
lopinavir (LPV/r) while those living in the  remaining cities
had levels of resistance to this class below 20%, as  shown in
Figure 1c (p < 0.001). Of note, resistance to  boosted-darunavir
(DRV/r) was detected in less than 5% of samples, except in RS,
where we found 14% of samples presenting resistance to that
PI. DRV/r was the only ARV drug that preserved susceptibility
regardless of patient’s origin.
The most frequent drug-resistance mutations after first,
second, and third failures are shown in Figure 2.  The over-
all mean number of active drugs was  8.8 ± 3.2, 9.2 ± 2.7, and
7.9 ± 3.9 for patients failing first, second, or third/more ARV
regimens, respectively. This number was similar for the differ-
ent cities, and ranged from eight (BA) to 10.5 (RJ). Some specific
mutations like 65R also showed a  great variation, with an over-
all mean prevalence of 4.4%, but ranging from 2.4% in RS,  to
6.2% in  RJ (p < 0.01).
The susceptibility pattern for all ARV drugs decreased over
subsequent failures, except for ETR and DRV/r which kept the
same level of activity against HIV-1 across initial or subsequent
ARV regimens failures, as summarized in  Figure 3.
The frequency of HIV-1 subtypes was also variable across
cities. As expected, most strains were classified as  subtype
B. The lowest (55.4%) and highest (78.6%) subtype B frequency
was observed in ES and BA, respectively. Subtype C was mainly
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Fig. 1 – (a) Susceptibility of HIV-1 (%)  to NRTI drugs after 1st
treatment failure in five cities of different Brazilian states.
(b) Susceptibility of HIV-1 to  NNRTI after 1st treatment
failure, according to patient’s origin. (C) Susceptibility (%) of
HIV-1 to PIs after 1st treatment failure, according to
patient’s origin.
detected in RS (31.7%), with other sites presenting a much
lower frequency (0.4–3.8%). Subtype F was less frequently
detected in RS (3.2%), with the highest frequencies observed in
CE (9.6%) and ES (11.5%). Recombinant BF strains were mostly
detected in BA and SP (4.7% each), but absent in CE. Other
multiple recombinant forms were also  detected in all sites,
ranging from 3.5% in RS  to  29.9% in ES (p  < 0.01 for comparisons
between sites).
Discussion
We  detected a  high variability in susceptibility rates to most
ARV drugs, according to  patient’s origin. The only ARV drug
with a  stable susceptibility rate, regardless of location, was
DRV/r. The most marked differences were found in  genotypic
tests from RS,  RJ, and CE, which showed a  distinct pattern
of susceptibility to  NRTI when compared to BA  or ES. We
observed that susceptibility rates to these drugs were signifi-
cantly higher in RJ in  comparison to other locations, while for
ddI and TDF the rates in RJ were different from BA, CE, and ES,
although similar to  that found in  RS.
Noteworthy, we detected a  high susceptibility rate (97%) for
AZT in RJ, in contrast to  CE, where only 55% of samples were
susceptible to  AZT. This may  reflect the  preferential use of AZT
or TDF as  first line therapy for the remaining sites, where we
observed a contrasting susceptibility between TDF and AZT,
but it was  not detected in RJ, where both drugs tested active
for almost 100% of samples. A potential explanation for this
fact could rely on distinct adherence rates to first line therapy
in different sites.
For NNRTI drugs the pattern was also different, with RS
showing an  almost two-fold higher (>50%) susceptibility rates
to EFV and NVP, in  comparison with other sites (25–35%,
p < 0.001 for comparison with other sites). In contrast, SP
showed the lowest susceptibility rates (around 10%) for these
drugs. Even for ETR, a  drug not used as first-line therapy, we
detected significant differences between sites, with lower sus-
ceptibility rates found in CE (48%), and higher rates in RS (92%)
and RJ (79%). For PI, we found a more  homogenous picture,
with CE, ES, RJ, and SP showing similar (around 80%) suscep-
tibility rates for all drugs in this class. However, in  RS  and BA
we  found much lower susceptibility rates for ATV/r, LPV/r, and
FPV/r.
Several previous studies have shown a  similar level of drug
resistance in different Brazilian regions; however the sample
size were usually smaller than ours, and most analyses were
restricted to  a  specific setting.8–13 Even in such populations we
can notice different prevalence of mutations like 103N. Toledo
et  al. evaluated a sample of 467 genotypic tests in  Parana state,
and detected a 46% prevalence of 103N mutation, while Westin
et al., in  Minas Gerais state found a  lower prevalence value
(32%).10,5 In Northeast Brazil, Cavalcanti et al. reported 58.7%
resistance to NNRTI, with 103N and 190A as the most prevalent
drug resistance mutations in this class.13
We  did not get information on most used first-line ARV
regimens in each city, but the Guidelines of the BMOH recom-
mends to use as  initial ART regimens two NRTI drugs plus EFV
or NVP.2 Our results suggest that compliance with these rec-
ommendations are distinct in different settings. The distinct
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Fig. 3 – Mean susceptibility rates to ARV drugs according to the number of previous failures to ART.
susceptibility rates detected suggest that in some settings
(BA and RS) protease inhibitors were more  frequently used as
the third drug either in  first-line or salvage regimens, while
in others NNRTI were the drug of choice for starting ther-
apy. Other alternative explanation is a wider previous use of
unboosted PI  (nelfinavir, indinavir, or atazanavir), since muta-
tions like 90M and 36I, and 71V are associated with use of these
drugs.
This possibility is supported by the finding of an inverse
relationship between susceptibility rates for PI, compared
to NNRTI drugs in the most divergent scenario: the lowest
susceptibility rates for PI  (especially ATV/r and FPV/r) and the
highest rates for NNRTI observed in RS. However, this was not
true for SP, where we detected the lowest susceptibility rates
for NNRTI, but no difference for PI. For ETR, the  trend was
similar, except for CE, where we detected 48% susceptibility,
against higher rates (62%-92%) in the remaining sites. Inter-
estingly, all ITRN showed better activity in  RJ, in comparison
to other cities, but NNRTI susceptibility rates were similar
across sites.
We know that previous use of NVP or EFV does not imply
in cross-resistance to ETR.14,15 However, if patients remain on
failing regimens containing these drugs for long enough time,
it is expected that viral variants with a more  complex DRM
profile will eventually be selected, which could lead to cross-
resistance to ETR. Again, the lack of information on how long
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these patients remained on failing regimens limits the reach
of such conclusions.
One interesting point is the finding that patients still pre-
serve a high GSS, even considering that most had previous
treatment failure to more  than one ARV regimen. Therefore
most failing patients can be successfully treated, with a high
likelihood to achieve sustained viral suppression. This is  in
accordance to recent publications by Brazilian authors show-
ing that even heavily pre-treated patients are able to reach
virological suppression after one year of a salvage regimen
including new ARV drugs/classes.16–19 On the other hand, low
resistance rates after failing regimens suggests that adherence
to therapy is a  major component of treatment failure in these
centers, and it  deserves a  careful evaluation by physicians and
health authorities.
The observed frequency of subtypes also demonstrates
the different epidemiological scenario in the distinct regions.
While most HIV strains belonged to subtype B, a clear
divergence regarding subtype C was  observed, which was
basically restricted to RS,  but was also present in SP, BA, and
ES, as already detected in previous studies.20,21 Noteworthy,
ES showed the lowest frequency of subtype B (55.4%), but
the highest proportion of other recombinants (29.9%), sug-
gesting a distinct dynamic of HIV-1 diversity in that area.
Whether subtypes variation could explain some differences
in mutational profiles observed in different cities, it  is still a
controversial issue.22–26
Although mutations associated with HIV-1 subtype C  (like
V106N) may confer resistance to EFV and NVP they have no
impact on ETV activity.27 In addition, in the  present study it
was not a frequent finding. Some recent data indicate that
subtype C-associated mutations conferring resistance to ETV
are rare, and most HIV-1 strains are susceptible to these drugs
after failure to first generation NNRTI.28 The higher suscepti-
bility rate to ETV detected in RS  (the site presenting the  higher
frequency of subtype C) underscores the absence of an asso-
ciation between HIV-1 subtype and susceptibility rate to  ETV.
Our study has  some clear limitations: we did not have
access to information on treatment outcomes after therapy
modification, which precluded confirmation that the observed
susceptibility rates held true in clinical practice. In addition,
information on adherence to therapy was not available, which
could explain some of study findings.
However, this study has  a large  sample size, and includes
patients from different Brazilian regions, providing informa-
tion on the most frequent DRM, and susceptibility rates for
patients in different phases of treatment of HIV infection.
In addition, it underscores the need for virological moni-
toring to detect drug failure, and to use genotypic tests to
guide the choice of salvage therapy regimens, as already sug-
gested in other studies on drug resistance in resource-limited
settings.29 Understanding the factors associated with failing
treatment, and the distinct resistance profile in early or later
treatment failures is an  essential step to face this persistent
challenge in HIV therapy.
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